Models of transient synovitis that can be controlled with antiinflammatory and analgesic drugs have been used to studypain amelioration. To this end, we aimed to determine the dose of intraarticularly administered E. coli LPS that inducedsigns of synovitis without systemic signs in clinically healthy male castrated sheep (n = 14). In phase 1, a single dose of LPS(0.5, 1.0, 1.5, or 2.0 ng in a total volume of 0.5 mL) was administered into the right stifle joint. In phase 2, a dose of LPS (1.0 or 2.0 μg) in 0.3 mL was administered to 4 naïve sheep. In phase 3, 4 sheep from phase 1 were inoculated after a 60 d washout period with either 0.5 or 1.0 μg of LPS. During the first 48 h after LPS administration, the following were performed: assessment of clinical parameters; scoring for lameness, pain on limb flexion, and local swelling; and ultrasonography of the joints were performed. The doses tested during phase 1 produced subtle signs. During phase 2, mild to moderate lameness with no evidence of systemic signs occurred at both doses. In phase 3, clinical responses were similar between the 0.5- and 1-μg doses. Signs of swelling were not observed at any time. Therefore, we consider the 0.5-μg to be the most appropriate for this model, because it was the lowest dose tested capable of causing lameness without signs of systemic inflammation in all animals.
The use of sheep in experiments is widespread and is increasing worldwide, and so is the need to develop species-specific anaesthetic techniques to ensure animal safety. Previous studies have mentioned several protocols involving the administration of alpha-2 adrenergic agonists in sheep; however, assessment of the efficacy and safety of these infusion techniques is still relatively new. Thus, the aim of the present study is to assess the effectiveness of detomidine constant rate infusion (CRI) in sheep by measuring the cardiovascular and respiratory parameters, blood gas variables and sedation scores. Eight adult female Santa Inês sheep received 20 µg/kg of detomidine hydrochloride intravenously as a bolus loading dose, followed by an infusion rate of 60 µg/kg/h. The heart rates and respiratory rates changed continuously during the CRI period. No arrhythmias were observed. The reduction in arterial partial pressure of oxygen (PaO) was not significant, but one animal showed signs of hypoxaemia (minimum PaO of 66.9 mmHg). The arterial partial pressure of carbon dioxide (PaCO) increased, but the animals did not become hypercapnic. The bicarbonate (HCO), pH and base excess (BE) tended towards metabolic alkalosis. The cardiac output (CO), stroke volume (SV), cardiac index (CI) and ejection fraction (EF%) showed no significant changes. The fractional shortening (FS%) decreased slightly, starting at T. Sedation scores varied between 3 (0/10) after sedation and during recovery and 7 (0/10) during CRI. We concluded that administering detomidine at an infusion rate of 60 µg/kg/h in Santa Inês sheep is a simple technique that produces satisfactory sedation for minimally invasive procedures.
Background The analgesic and cardiorespiratory effects of ketamine, fentanyl, or ketamine-fentanyl constant rate infusion (CRI) in dogs undergoing mastectomy were evaluated. Seventeen female dogs received CRI of ketamine (GK [n = 6]: bolus 0.5 mg/kg; CRI 20 µg/kg/min in intra- and postoperative periods], fentanyl (GF [n = 5]: bolus 20 µg/kg; intraoperative CRI 5 20 µg/kg/hour and postoperative CRI 2 20 µg/kg/hour), or combination of ketamine-fentanyl (GKF [n = 6]: aforementioned doses) for 8 h. Cardiorespiratory, blood gas analyses, plasma drug concentrations, sedation score (SS), Pain Scores were evaluated. Results The heart rate decreased in the GF and GKF (p < 0.04); the mean arterial pressure was lower in the GKF than in the GK at 35 min (p < 0.001). Maximum plasma concentrations were observed 5 min after bolus in the GK (2847.06 ± 2903.03 ng/mL) and GKF (2811.20 ± 1931.76 ng/mL). Plasma concentration in intraoperative period of ketamine was of > 100 ng/mL in 5/5 and 2/5 animals in the GKF and GK, respectively; and > 1.1 ng/mL of fentanyl in 4/5 and 3/5 in GKF and GF, respectively. Conclusion Ketamine with/without fentanyl provided analgesia without significant cardiorespiratory and guaranteed the minimal plasma levels with analgesic potential during the 8 h.
A longitudinal study was conducted to identify the morphological development of eyes and head of Jersey cattle at different ages. A total of 48 healthy Jersey cattle, 1 to 58 months of age, were included in the study. Ophthalmologic examinations were performed to identify healthy cattle to form the age groups: GI (1‐ to 11‐month‐old), GII (16‐ to 24‐month‐old) and GIII (25‐ to 58‐month‐old). The animals were physically restrained and examined by transcorneal ultrasound of both eyes; the axial length (AxL), corneal thickness (CO), lenticular thickness (L), depth of the anterior (AC) and vitreous (VC) chambers were evaluated. The cranial measurements obtained included the total, cranial, and nasal lengths and widths. Subsequently, the cephalic index (CI) was calculated. The AxL (GI: 2.83 cm; GII: 3.16 cm; GIII: 3.24 cm), AC (GI: 0.44 cm; GII: 0.53 cm; GIII: 0.53 cm), L (GI: 0.88 cm; GII: 1.01 cm; GIII: 1.04 cm) and VC (GI: 1.44 cm; GII: 1.55 cm; GIII: 1.59 cm) increased (p ≤ .001) according to age, but the CO (GI: 0.07 cm; GII: 0.08 cm; GIII: 0.08 cm) (p > .05) did not. The total length (GI: 30.83 cm; GII: 43.29 cm; GIII: 44.15 cm), cranial length (GI: 18.11 cm; GII: 23.82 cm; GIII: 22.69 cm), nasal length (GI: 12.72 cm; GII: 19.47 cm; GIII: 21.46 cm) and nasal width (GI: 26.22 cm; GII: 33.82 cm; GIII: 34.00 cm) increased (p < .001), and the CI (GI: 85.66 cm; GII: 78.15 cm; GIII: 77.02 cm) decreased (p < .001). The AxL correlated positively (p < .001) with the cranial length and width and negatively with the CI (p > .05). The ocular biometry of Jersey cattle correlates with their cranial measurements at different ages. With increasing age, the eyes and the head grow, establishing growth curves similar to those of other mammals.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.